Allogeneic bone marrow transplantation (BMT) is a successful therapy for patients with severe aplastic anemia (SAA). A rare complication after BMT for SAA is the development of acute leukemia ([@b10-gmb-35-734]). Cytogenetic or variable number tandem repeat (VNTR) analysis has shown that, in these rare cases, the leukemia originates in host cells. Donor cell leukemia (DCL) or donor cell myelodysplastic syndrome are complications that have been observed not only after hematopoetic transplantation with progenitor cells harvested from bone marrow and peripheral blood, but also after cord blood transplantation ([@b2-gmb-35-734]). Most of the DCL cases occurred in patients transplanted for acute leukemias. Only six cases of secondary leukemia in donor cells after BMT for SAA have been reported so far ([@b10-gmb-35-734]; [@b9-gmb-35-734]; [@b2-gmb-35-734]; [@b13-gmb-35-734]; [@b5-gmb-35-734]; [@b7-gmb-35-734]). Hypotheses offered to explain the development of DCL include transfer of oncogenic material from host to donor cells, immunosuppression after BMT leading to inadequate immune surveillance, leukemic transformation of engrafted cells, and occult leukemia in the donor cells ([@b14-gmb-35-734]). Here we report on a case of monosomy 7 in DCL following BMT for SAA in a Brazilian patient and discuss its possible causes.

In January 2007, a 23-year-old man diagnosed with SAA was referred to our center for allogenic bone marrow transplantation from an HLA-identical sister. Prior to the procedure, the bone marrow aspirate revealed marked hypocellularity with a predominance of mature lymphocytes, and the bone marrow biopsy showed a 5% cellularity. Conventional cytogenetic analysis showed a normal 46,XY karyotype in 24 metaphases. The conditioning regimen consisted of cyclophosphamide and ATG. Cyclosporin A and methotrexate were administered to prevent graft-versus-host disease (GVHD). The engraftment occurred on day 25 (\> 500/mm^3^ neutrophils for 3 consecutive days). After BMT, the patient developed multiple infections and persistent neutropenia. His bone marrow aspirate did not show any blasts or dysplasias. In September 2009, the patient's neutropenia worsened and he received granulocyte colony stimulating factor (G-CSF). Nevertheless, there was no clinical improvement and he developed anemia, neutropenia and thrombocytopenia. In December 2009, the treatment with G-CSF was discontinued. A bone marrow examination was performed and its result was consistent with acute myeloid leukemia (AML). The immunophenotype analysis showed 30% of blasts with myeloid and monocytic component features (AML M4/M5). Cytogenetic analysis showed 100% donor cells, and 7.6% of them presented monosomy 7 ([Figure 1A](#f1-gmb-35-734){ref-type="fig"}). The karyotype of the donor bone marrow sample was normal in 40 metaphases analyzed after G-banding and FISH analysis detected no monosomy 7 in 200 cells studied ([Figure 1B](#f1-gmb-35-734){ref-type="fig"}). In January 2010, the patient underwent a second transplantation with G-CSF-mobilized peripheral blood cells from the same donor. The engraftment occurred on day 10. However, 15 days after the transplantation, the patient died due to refractory septic shock.

Literature reports on chromosome abnormalities resulting in hematological malignancies in donor cells after BMT are rare. Only a few cases of DCL have been reported after BMT for SAA. In the current case, we detected monosomy 7 in donor cells at day 1029 after BMT. Immunophenotype and morphological analysis confirmed the acute myeloid leukemia M4/M5 diagnosis at that time. Monosomy 7 in DCL after BMT for SAA was previously described by [@b12-gmb-35-734]. In their case, the donor cells were identified by microsatellite marker analysis, since patient and donor were both females. In our case, a male patient received a graft from his sister, and monosomy 7 was detected only in the XX donor cells. Monosomy 7 was also reported in one case of transient donor cell-derived myelodysplastic syndrome ([@b15-gmb-35-734]) and in one case of donor cell-derived acute monoblastic leukemia ([@b6-gmb-35-734]), after unrelated cord blood transplantation. In a recent study, [@b17-gmb-35-734] described 10 cases of DCL, of which six had monosomy 7/del(7q). Thus, monosomy 7 arises as a recurrent chromosome aberration in donor cell leukemia after hematopoietic stem cell transplantation. In general, monosomy 7 represents one of the most common chromosomal abnormalities in myelodysplastic syndromes, being present in approximately 50% of therapy-related cases ([@b3-gmb-35-734]). It probably arises at the level of myeloid progenitor cells and is usually associated with a very poor prognosis ([@b4-gmb-35-734]). To investigate the possibility of occult leukemia cells in the donor, we performed conventional cytogenetic and FISH analysis, but no monosomy 7 was detected in the donor bone marrow sample. The mechanisms underlying the development of chromosomal abnormalities in donor cells are not fully understood so far. The microenvironment of our patient's bone marrow may have played a role in the development of monosomy 7 in the normal donor cells. This possibility was also suggested by [@b12-gmb-35-734]. We further believe that the impact of post-BMT immunosuppression, G-CSF utilization and local viral infection cannot be precisely assessed. A significantly increased incidence of MDS/AML was reported by the European Group for Blood and Marrow Transplantation in SAA patients receiving immunosuppressive therapy and G-CSF compared to those not receiving G-CSF ([@b16-gmb-35-734]). Some authors hypothesized that treatment with G-CSF might have played a role in the transformation of SAA into AML with monosomy 7 ([@b8-gmb-35-734]). Another Japanese study demonstrated a substantial risk in children with SAA receiving G-CSF, and a high frequency of deletion of the long arm of chromosome 7 and monosomy 7, was identified by FISH ([@b11-gmb-35-734]). Notwithstanding, in a more recent study, [@b1-gmb-35-734] argued that the available clinical data do not provide evidence that G-CSF can transform donor normal hematopoietic stem cells in the absence of predisposing factors. The host microenvironment could play a role in the leukemic transformation. Our patient received G-CSF support 32 months after BMT, and monosomy 7 was detected two months after starting its use.

Our case highlights the fact that donor cell leukemia is an important entity in understanding the leukemogeneifc process.

Associate Editor: Angela M. Vianna-Morgante
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